BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Center for RNA Biomedicine - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Center for RNA Biomedicine
X-ORIGINAL-URL:https://rna.umich.edu
X-WR-CALDESC:Events for Center for RNA Biomedicine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Detroit
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Detroit:20221010T160000
DTEND;TZID=America/Detroit:20221010T170000
DTSTAMP:20260512T054159
CREATED:20220902T191232Z
LAST-MODIFIED:20220920T185235Z
UID:10559-1665417600-1665421200@rna.umich.edu
SUMMARY:RNA Innovation Seminar: Polly Hsu\, Michigan State University
DESCRIPTION:“Roadblocks on mRNAs? Gene Expression Regulation by Upstream Open Reading Frames in Plants”\nPolly Hsu\, Ph.D.\nAssistant Professor\nBiochemistry and Molecular Biology\nMichigan State University \n  \n  \nFlyer in PDF \nIn-person: BSRB\, ABC seminar rooms / hybrid link \nKeywords: translation\, uORFs\, nonsense-mediated decay \nAbstract: 30-70% of mRNAs in humans\, mice and plants contain short ORFs\, called upstream ORFs (uORFs)\, in their 5’ leader sequences. The translation of uORFs is expected to repress the protein synthesis of their downstream main ORF (mORF) and to trigger mRNA degradation\, presumably through nonsense-mediated decay (NMD). I will share our current progress investigating the global and gene-specific mechanisms by which uORFs regulate gene expression in Arabidopsis and tomato. I will discuss 1) different classes of uORFs revealed by Ribo-seq\, 2) the roles of uORFs on transcription factor and protein kinase genes\, 3) the mRNA stability of uORF-containing genes\, and 4) cellular regulatory mechanisms to include or avoid uORFs on mRNA sequences.
URL:https://rna.umich.edu/events/polly-hsu/
LOCATION:MI
CATEGORIES:Seminar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Detroit:20221017T160000
DTEND;TZID=America/Detroit:20221017T170000
DTSTAMP:20260512T054159
CREATED:20220902T191827Z
LAST-MODIFIED:20221013T144443Z
UID:10562-1666022400-1666026000@rna.umich.edu
SUMMARY:RNA Therapeutics Seminar: John Cooke\, M.D.\, Ph.D.\, Medical Director\, Center for RNA Therapeutics\, Houston Methodist
DESCRIPTION:“The Democratization of RNA Therapeutics”\nJohn Cooke\, M.D.\, Ph.D.\nJoseph C. “Rusty” Walter and Carole Walter Looke Presidential Distinguished Chair in Cardiovascular Disease Research\, Department of Cardiovascular Sciences\nChair\, Department of Cardiovascular Sciences\nProfessor of Cardiovascular Sciences\, Academic Institute\nFull Member\, Research Institute\nDirector\, Center for Cardiovascular Regeneration\nMedical Director\, Center for RNA Therapeutics\nHouston Methodist \n  \nFlyer in PDF \nIn-person: BSRB\, ABC room with zoom option \nAbstract: mRNA therapeutics is a disruptive therapeutic technology\, as small biotech startups\, as well as academic groups\, can rapidly develop new and personalized mRNA constructs. In the Texas Medica Center\, we have established a Center for RNA Therapeutics that comprises faculty innovators\, as well as a translational assembly line to bring great RNA ideas to life. Academic groups and small companies work with us as we innovate\, design\, synthesize\, purify\, encapsulate and test mRNA therapies. In addition to providing pre-clinical GLP testing\, we have established cGMP-compliant manufacturing capability and quality control methods to support pre-clinical GLP studies and phase I clinical trials; and have a first-in-man phase 1 clinical trial unit. To support phase II and phase III trials\, and commercialization\, we have licensed our proprietary manufacturing processes to VGXI Inc\, a local company with large-batch manufacturing capabilities for DNA-based gene therapies. With this collaboration\, we have built a seamless transition for academic groups and small companies to go from pre-clinical development and first-in-man clinical trials supported by our hospital-based program\, to late-stage clinical trials and commercialization supported by our industry partner VGXI\, Inc. \n  \nFlyer in PDF
URL:https://rna.umich.edu/events/john-cooke/
LOCATION:MI
END:VEVENT
END:VCALENDAR